Join to View Full Profile
1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-6161
Join Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 1 invite waiting! - Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Alessandra Ferrajoli, MD is an oncologist in Houston, Texas. She is currently licensed to practice medicine in Texas, Florida, and Oklahoma.
Education & Training
University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 1998 - 2001- University of Texas Health Science Center at HoustonResidency, Internal Medicine, 1995 - 1998
University of Perugia Faculty of MedicineClass of 1988
Certifications & Licensure
FL State Medical License 2021 - Present
TX State Medical License 2000 - 2026
OK State Medical License 2020 - 2021
American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia.Courtney D DiNardo, Wei-Ying Jen, Koichi Takahashi, Tapan M Kadia, Sanam Loghavi
Leukemia. 2025-04-01 - Decreased Transfusions in Premenopausal Patients Undergoing Allogeneic Hematopoietic Stem-Cell Transplantation Given Leuprolide According to an Abnormal Uterine Bleedi...Denise R Nebgen, Lee Cheng, Amin M Alousi, Alessandra Ferrajoli
JCO Oncology Practice. 2025-04-01 - Hyper-CVAD and Sequential Blinatumomab Without and With Inotuzumab in Young Adults With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leu...Hagop Kantarjian, Nicholas J Short, Nitin Jain, Fadi G Haddad, Tapan Kadia
American Journal of Hematology. 2025-03-01
Authored Content
- L-carnitine and Vitamin B Complex for the Treatment of Pegasparaginase-InducedFebruary 2018
- Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA101) (iFCG) TreatmentOctober 2017
- 'The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine IsOctober 2017
Press Mentions
NCCN Awards Grants to Improve Care for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaDecember 4th, 2024- MD Anderson Research Highlights for September 19, 2024September 19th, 2024
- MRD: Powerful Metric for CLL ResearchApril 5th, 2023
- Join now to see all
